GRCL News and Press, Gracell Biotechnologies Inc. From 11/23/21

Gracell Biotechnologies Announces Senior Management Team Share Purchase Plan PR Newswire SUZHOU, China and PALO ALTO, Calif. , Nov. 23, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage bi...

Gracell Biotechnologies Inc. (NASDAQ: GRCL) has reported that the U.S. FDA has granted Orphan Drug Destination for GC012F, Gracell’s FasTCARE-enabled BCMA/CD19 dual targeting CAR-T cell therapy for treatment of multiple myeloma.  “As our lead candidate curre...

Gainers: iSpecimen (NASDAQ:ISPC) +85%. Navitas Semiconductor (NYSE:NVTSW) +29%. Vonage (NASDAQ:VG) +26%. Astra (NASDAQ:ASTR) +25%. Avaya (NYSE:AVYA) +25%. Lee Enterprises (NASDAQ:LEE) +24%. Cloopen Group (NYSE:RAAS) +24%. MultiPlan (NYSE:MPLN) +23%. Partner (NASDAQ:PTNR) +20%. Camber Energy (...

Gainers: iSpecimen (NASDAQ:ISPC) +120%, MultiPlan (NYSE:MPLN) +21%, Provention Bio PRVB +20%, Stoke Therapeutics (NASDAQ:STOK) +16%, Star Equity STRR +14%. Losers: Gracell Biotechnologies (NASDAQ:GRCL) -31%, Aurinia Pharmaceuticals (NASDA...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re starting off the final day of trading this week with a look at the biggest pre-market stock movers for Friday! Source: Shutterstock There’s plenty of news moving stock today...

Gracell Biotechnologies (NASDAQ:GRCL) soars 31.5% premarket after the FDA granted Orphan Drug Designation for GC012F, a FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma. Among the benefits of Orphan Drug status in the U.S. is a seven-...

Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma PR Newswire SUZHOU and SHANGHAI, China , and PALO ALTO, Calif. , Nov. 19, 202...

SUZHOU, China and PALO ALTO, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...

Gracell Biotechnologies (NASDAQ:GRCL): Q3 GAAP EPS of -RMB0.70. Cash and equivalents of RMB1.96B Press Release For further details see: Gracell Biotechnologies reports Q3 results

SUZHOU, China and PALO ALTO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...